Top Markets
Coin of the day
Healios K.K. Healios K.K.

Healios K.K.

4593
Kedudukan dalam Saham #17189
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011,... Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Harga Saham
$1.89
Modal Pasaran
$254.55M
Perubahan (1 hari)
-2.03%
Perubahan (1 tahun)
-48.53%
Negara
JP
Perdagangan Healios K.K. (4593)

Kategori

Sejarah hasil dividen untuk Healios K.K. (4593)
Hasil dividen (TTM) bagi Healios K.K. (simbol saham: 4593) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Healios K.K. (4593) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
0.00%
US
0.00%
NL
0.00%
US
2.48%
AU
0.00%
CH